The frequency of L1CAM positivity was particularly high in several subtypes of neural and neuroendocrine neoplasms (up to 100%), endometrium carcinoma (3.9–50.0%), ovarian cancer (10.0–33.1%), cervical adenocarcinoma (9.1%), malignant melanoma (24.1–31.3%), malignant mesothelioma (16.7–20.8%), adenocarcinomas of the gastrointestinal and the biliopancreatic tract (4.9–14.1%) and in urothelial tumors (up to 10.3%). Here, L1CAM is linked to adenocarcinoma.